Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
May 31, 2026 0.00
February 28, 2026 0.00
November 30, 2025 0.00
August 31, 2025 0.00
May 31, 2025 0.00
February 28, 2025 0.00
November 30, 2024 0.00
August 31, 2024 0.00
May 31, 2024 0.00
February 29, 2024 0.00
November 30, 2023 0.00
August 31, 2023 0.00
May 31, 2023 0.00
February 28, 2023 0.00
November 30, 2022 0.00
August 31, 2022 0.00
May 31, 2022 0.00
February 28, 2022 0.00
November 30, 2021 0.00
August 31, 2021 0.00
May 31, 2021 0.00
February 28, 2021 0.00
November 30, 2020 0.00
August 31, 2020 0.00
May 31, 2020 0.00
Date Value
February 29, 2020 0.00
November 30, 2019 0.00
August 31, 2019 0.00
May 31, 2019 0.00
February 28, 2019 -0.0675M
November 30, 2018 -7.150M
August 31, 2018 -0.50M
May 31, 2018 0.085M
February 28, 2018 -1.05M
November 30, 2017 0.00
August 31, 2017 -0.5556M
May 31, 2017 -2.918M
February 28, 2017 -0.4585M
November 30, 2016 -0.384M
August 31, 2016 0.00
May 31, 2016 0.00
February 29, 2016 -0.094M
November 30, 2015 0.00
August 31, 2015 -0.0302M
May 31, 2015 0.00
February 28, 2015 0.00
November 30, 2014 -0.0783M
May 31, 2014 -0.002M
February 28, 2014 -0.001M
November 30, 2013 -0.10M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
GB Sciences, Inc. --
Arvinas, Inc. -0.50M
Fulcrum Therapeutics, Inc. -0.356M
Definium Therapeutics, Inc. -758.70M